- Home
- DT vs PODD Comparison
DT vs PODD Comparison
Compare DT & PODD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DT | PODD |
|---|---|---|
| Founded | 2005 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Medical/Dental Instruments |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 10.5B |
| IPO Year | 2019 | 2007 |
Fundamental Metrics
Financial Performance| Metric | DT | PODD |
|---|---|---|
| Price | $40.71 | $155.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 26 | 21 |
| Target Price | $51.77 | ★ $341.48 |
| AVG Volume (30 Days) | ★ 5.6M | 1.3M |
| Earning Date | 05-13-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 205.77 | N/A |
| EPS | 0.48 | ★ 1.30 |
| Revenue | $1,698,683,000.00 | ★ $2,708,100,000.00 |
| Revenue This Year | $21.74 | $24.55 |
| Revenue Next Year | $14.85 | $19.18 |
| P/E Ratio | ★ $84.15 | $123.17 |
| Revenue Growth | 18.75 | ★ 30.73 |
| 52 Week Low | $31.64 | $148.31 |
| 52 Week High | $57.55 | $354.88 |
Technical Indicators
Market Signals| Indicator | DT | PODD |
|---|---|---|
| Relative Strength Index (RSI) | 67.39 | 28.63 |
| Support Level | $38.50 | N/A |
| Resistance Level | $41.02 | $205.95 |
| Average True Range (ATR) | 1.24 | 9.07 |
| MACD | 0.61 | -1.86 |
| Stochastic Oscillator | 95.32 | 12.92 |
Price Performance
Historical ComparisonAbout DT Dynatrace Inc.
Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.
About PODD Insulet Corporation
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, approximately 500,000 insulin-dependent diabetic patients are using it worldwide.